Modular iPSC workflow for allogeneic cell therapy applications: from iPSCs to iNKs

The transition of induced pluripotent stem cell (iPSC)-derived cell therapies from research to clinical applications faces significant barriers, including limited supply of regulatory-compliant reagents, scale-up challenges, and variable differentiation protocols. This article describes modular, xeno-free workflow solutions that address these limitations through systematic integration of compliant reagents, closed-system processing, and standardized differentiation protocols, using natural killer cell generation as a model therapeutic application.